Patent intelligence · EP
EP 4031157
BAKTERIENSTÄMME, IHRE ZUSAMMENSETZUNGEN UND IHRE VERWENDUNG ZUR BEHANDLUNG GASTROINTESTINALER ERKRANKUNGEN
BAKTERIENSTÄMME, IHRE ZUSAMMENSETZUNGEN UND IHRE VERWENDUNG ZUR BEHANDLUNG GASTROINTESTINALER ERKRANKUNGEN
Patent details — EP 4031157
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Jul 27, 2022
- Expiration
- Jul 22, 2042
- Applicant
- SOFAR SPA [IT]
- CPC classes
- A61K 35/ 745 A I, A61K/35745, A61K/35747, A61P 1/ 00 A I
Quick answer
EP 4031157 (BAKTERIENSTÄMME, IHRE ZUSAMMENSETZUNGEN UND IHRE VERWENDUNG ZUR BEHANDLUNG GASTROINTESTINALER ERKRANKUNGEN) is held by SOFAR SPA [IT]. Status: granted. Granted Jul 27, 2022. Expires Jul 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SOFAR SPA [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 35/ 745 A I, A61K/35745, A61K/35747, A61P 1/ 00 A I, A61P 29/ 00 A I, A61P/100
More from SOFAR SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026027669
BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB
granted -
IT 202300014295
COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO
granted -
IT 202300012522
FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.
granted -
AU 2023257308
USES OF FARNESOID X RECEPTOR AGONISTS
granted -
IT 202300006237
COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.
granted -
IT 202300001434
PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.
granted -
CA 3263063
VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)
granted -
IT 202200013882
PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.
granted
Frequently asked questions
What is US patent 4031157?
EP 4031157 (BAKTERIENSTÄMME, IHRE ZUSAMMENSETZUNGEN UND IHRE VERWENDUNG ZUR BEHANDLUNG GASTROINTESTINALER ERKRANKUNGEN) is held by SOFAR SPA [IT]. Status: granted. Granted Jul 27, 2022. Expires Jul 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 4031157?
SOFAR SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 4031157 expire?
Our index shows an expiration date of Jul 22, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.